Skip to main content

Remote Job Finders (RJF)

‘Worse than expected’ Wainua data muddies water for TTR silencers

AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin silencer trial “further confuses the picture” for Wainua when combined with the standard of care for ATTR-CM, analysts say.
Scroll to top